Mersana Therapeutics Executive Compensation (FY24)
MRSN · Executive and director compensation, fiscal 2022 to 2024
The Mersana Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (DEF 14A): April 29, 2025
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
240 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Huber: $2,601,249 → $1,613,754 (38.0% lower)
CEO pay ratio: 12:1 → 5:1 (58.3% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Mersana Therapeutics' chief executive and what were they paid?
Michael Huber was paid $1,613,754 in total compensation as President and Chief Executive Officer for fiscal 2024. Huber's total was 38.0% lower than the $2,601,249 reported for fiscal 2023.
Which companies are in Mersana Therapeutics' peer group?
The disclosed peer group names Adicet Bio, Inc., Black Diamond Therapeutics, Inc., C4 Therapeutics, Inc., Century Therapeutics, Inc. and CytomX Therapeutics, Inc., among others.
What is Mersana Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 5:1 for fiscal 2024, against median employee compensation of $316,460.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Anna Protopapas Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Arvin Yang Former Senior Vice President, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Brian DeSchuytner Senior Vice President, Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Timothy Lowinger Senior Vice President, Chief Science and Technology Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alejandra Carvajal Senior Vice President, Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Mohan Bala Senior Vice President, Chief Development Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | — | — not reconciled |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Anna Protopapas Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Huber President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Arvin Yang Former Senior Vice President, Chief Medical Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Brian DeSchuytner Senior Vice President, Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Timothy Lowinger Senior Vice President, Chief Science and Technology Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alejandra Carvajal Senior Vice President, Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mohan Bala Senior Vice President, Chief Development Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Huber President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Brian DeSchuytner Senior Vice President, Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mohan Bala Senior Vice President, Chief Development Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Timothy Lowinger Senior Vice President, Chief Science and Technology Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alejandra Carvajal Senior Vice President, Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Alejandra Carvajal | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Alejandra Carvajal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Brian DeSchuytner | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Brian DeSchuytner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Martin Huber | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Martin Huber | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mohan Bala | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mohan Bala | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Timothy B. Lowinger | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Timothy B. Lowinger | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Brian DeSchuytner | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Alejandra Carvajal | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Timothy Lowinger | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Mohan Bala | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Martin Huber | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
David Mott Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Lawrence M. Alleva | ◇ | — | ◇ | — | — | — | ◇ |
Willard Dere, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Kristen M. Hege, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Andrew A. F. Hack, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Allene M. Diaz | ◇ | — | ◇ | — | — | — | ◇ |
Anna Protopapas | ◇ | — | ◇ | — | — | — | ◇ |
Martin Huber, M.D served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Stock Option.
Stock ownership guideline: Set robust executive officer and non-employee director stock ownership guidelines
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Adicet Bio, Inc. ACET
- Black Diamond Therapeutics, Inc. BDTX
- C4 Therapeutics, Inc. CCCC
- Century Therapeutics, Inc. IPSC
- CytomX Therapeutics, Inc. CTMX
- Fate Therapeutics, Inc. FATE
- Foghorn Therapeutics, Inc. FHTX
- IGM Biosciences, Inc. IGMS
- Inovio Pharmaceuticals, Inc. INO
- iTeos Therapeutics, Inc. ITOS
- Monte Rosa Therapeutics, Inc. GLUE
- Omega Therapeutics, Inc. symbol not shown
- Prelude Therapeutics Incorporated PRLD
- Pyxis Oncology, Inc. symbol not shown
- Tango Therapeutics, Inc. TNGX
- TScan Therapeutics, Inc. TCRX
- Verastem, Inc. VSTM
- Vor Biopharma, Inc. VOR
- Werewolf Therapeutics, Inc. HOWL
- Zymeworks, Inc. ZYME
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
What this page does not include
Everything above is a fact Mersana Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Mersana Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
240 figures on this page, cited to the filing that reported them.
240 cited to the filing
Documents cited
- 0001104659-25-0404482024 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · Non-Employee Director Compensation · and 1 more section
- 0001104659-24-0522352023 Summary Compensation Table
- 0001104659-23-0518562022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Mersana Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/MRSN (accessed 2026).
Short form: data: Velarion
The Mersana Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Mersana Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Mersana Therapeutics discloses
The companies named in MRSN's own disclosed peer group.
Black Diamond Therapeutics, Inc.C4 Therapeutics, Inc.Century Therapeutics, Inc.Fate Therapeutics, Inc.Foghorn Therapeutics, Inc.IGM Biosciences, Inc.Inovio Pharmaceuticals, Inc.iTeos Therapeutics, Inc.Monte Rosa Therapeutics, Inc.Prelude Therapeutics IncorporatedTango Therapeutics, Inc.TScan Therapeutics, Inc.Verastem, Inc.Vor Biopharma, Inc.Zymeworks, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}